Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Four years late, 50% success rate, Lilly’s solanezumab stays in PhIII

This article was originally published in Scrip

Executive Summary

The earliest possible date that solanezumab is likely to reach the US Alzheimer’s market is now the end of 2017, four years later than Eli Lilly had initially hoped when it started its EXPEDITION clinical trial program. Assuming approval in mild Alzheimer’s disease, with additional off-label use in MCI patients, Datamonitor forecasts solanezumab to achieve sales of $4.0 billion across the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) in 2021.

Advertisement

Related Content

Surprise! It’s A Phase III Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019733

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel